Condition: Non-small Cell Lung Cancer · Sponsor: Merck Sharp & Dohme LLC
This is a phase 3, randomized, double-blind study of adjuvant calderasib plus subcutaneous pembrolizumab and berahyaluronidase alfa (MK-3475A) versus adjuvant placebo plus MK-3475a in participants with completely resected stage IIA-IIIB (N2), KRAS G12C-mutant non-small cell lung cancer following receipt of either neoadjuvant pembrolizumab plus chemotherapy or adjuvant chemotherapy. The primary goal of the study is to compare adjuvant calderasib plus MK-3475A to adjuvant placebo plus MK-3475A with respect to disease-free survival (DFS) as assessed by the investigator.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Instituto Alexander Fleming ( Site 0310) | Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina | Recruiting |
| Sanatorio Parque ( Site 0311) | Rosario, Santa Fe Province, Argentina | Recruiting |
| Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0306) | CABA, Argentina | Recruiting |
| Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 0309) | CABA, Argentina | Recruiting |
| Northern Beaches Hospital ( Site 3009) | Frenchs Forest, New South Wales, Australia | Recruiting |
| Moncton Hospital ( Site 0200) | Moncton, New Brunswick, Canada | Recruiting |
| Centre Hospitalier de l'Université de Montréal ( Site 0219) | Montreal, Quebec, Canada | Recruiting |
| Peking Union Medical College Hospital ( Site 2105) | Beijing, Beijing Municipality, China | Recruiting |
| Chongqing University Three Gorges Hospital ( Site 2138) | Chongqing, Chongqing Municipality, China | Recruiting |
| The First Affiliated Hospital Of Fujian Medical University ( Site 2123) | Fuzhou, Fujian, China | Recruiting |
| Sun Yat-sen University Cancer Center ( Site 2134) | Guangzhou, Guangdong, China | Recruiting |
| Guangxi Medical University Cancer Hospital ( Site 2115) | Nanning, Guangxi, China | Recruiting |
+ 60 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07431827